Resolution of the Research Council of Experts on the place of netakimab, a new interleukin-17a inhibitor, in the therapy of ankylosing spondylitis
.
Saved in:
| Main Author: | article Editorial |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2020-06-01
|
| Series: | Научно-практическая ревматология |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2906 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Resolution of the Scientific Council of Experts: “The place of netakimab, a new inhibitor of IL-17A, in the treatment of psoriatic arthritis
by: article Editorial
Published: (2020-09-01) -
Course of uveitis in patients with ankylosing spondylitis during the interleukin 17 inhibitors therapy
by: A. A. Godzenko, et al.
Published: (2023-10-01) -
Comparative pharmacoeconomic effectiveness of interleukin-17 inhibitors for the treatment of ankylosing spondylitis
by: T. V. Dubinina, et al.
Published: (2022-12-01) -
Pharmacoeconomic analysis of netakimab in the treatment of ankylosing spondylitis: perspective of Russian healthcare system
by: A. V. Rudakova, et al.
Published: (2025-02-01) -
INTERLEUKIN-17A IS A NEW TARGET OF ANTICYTOKINE THERAPY FOR ANKYLOSING SPONDYLITIS
by: Sh. F. Erdes
Published: (2016-09-01)